Statins and the Liver

Cynthia Herrick, Samira Bahrainy, Edward A. Gill

Research output: Contribution to journalReview articlepeer-review

5 Scopus citations


Lipid lowering, particularly with 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors ("statins"), reduces the risk of cardiovascular disease. Patients with chronic liver disease present challenges to the use of lipid medications. In the case of most liver disorders, the concern has been one of safety. There is evidence that most lipid-lowering medications can be used safely in many situations, although large outcomes trials are lacking. This review examines lipid physiology and cardiovascular risk in specific liver diseases and reviews the evidence for lipid lowering and the use of statins in chronic liver disease.

Original languageEnglish
Pages (from-to)117-128
Number of pages12
JournalEndocrinology and Metabolism Clinics of North America
Issue number1
StatePublished - Mar 1 2016


  • Chronic liver disease
  • Dyslipidemia
  • Hepatic transaminases
  • Statins


Dive into the research topics of 'Statins and the Liver'. Together they form a unique fingerprint.

Cite this